Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Edition By
Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete
,Chapter 01: Drug Definitions, Standards, and Information Sources
A A A A A A A
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
A A A A A A A
MULTIPLEACHOICE
WhichAnameAidentifiesAaAdrugAlistedAbyAtheAUSAFoodAandA
DrugAAdministrationA(FDA)?
Brand
Nonproprietary
Official
Trademark
ANS:AC
TheAofficialAnameAisAtheAnameAunderAwhichAaAdrugAisAlistedA
byAtheAFDA.ATheAbrandAname,AorAtrademark,AisAtheAnameAgi
venAtoAaAdrugAbyAitsAmanufacturer.ATheAnonproprietary,AorAg
eneric,AnameAisAprovidedAbyAtheAUnitedAStatesAAdoptedANa
mesACouncil.
DIF: CognitiveALevel:AKnowledge REF:Ap.A9
OBJ:A1NAT:ANCLEXAClientANeedsACategory:ASafe,AEffectiveACare
EnvironmentATOP:AANursingAProcessAStep:AAssessment CON:
PatientAEducation
WhichAsourceAcontainsAinformationAspecificAtoAnutritionalAsupplements?
USPADictionaryAofAUSANA&AInternationalADrugANames
NaturalAMedicinesAComprehensiveADatabase
UnitedAStatesAPharmacopoeia/NationalAFormularyA(USPANF)
DrugAInteractionAFacts
ANS:AC
UnitedAStatesAPharmacopoeia/NationalAFormularyAcontainsAinformationAspecificAtoAnutrition
alAsupplements.AUSPADictionaryAofAUSANA&AInternationalADrugANamesAisAaAcompilationAofAd
rugAnames,ApronunciationAguide,AandApossibleAfutureAFDAAapprovedAdrugs;AitAdoesAnotAinclud
eAnutritionalAsupplements.ANaturalAMedicinesAComprehensiveADatabaseAcontainsAevidence-
basedAinformationAonAherbalAmedicinesAandAherbalAcombinationAproducts;AitAdoesAnotAinclude
AinformationAspecificAtoAnutritionalAsupplements.ADrugAInteractionAFactsAcontainsAcomprehen
siveAinformationAonAdrugAinteractionAfacts;AitAdoesAnotAincludeAnutritionalAsupplements.
DIF: CognitiveALevel:AKnowledge REF: p.A4 OBJ:A3
NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
TOP: NursingAProcessAStep:AAssessment CON:ANutritionA|APatientAEducation
WhichAdrugAreferenceAcontainsAdrugAmonographsAthatAdescribeAallAdrugsAinAaAtherapeuticAcla
ss?Aa.ADrugAFactsAandAComparisons
,TestABankAForAClayton’sABasicAPharmacologyAforANursesA19thAEdition 3
DrugAInteractionAFacts
HandbookAonAInjectableADrugs
Martindale—TheACompleteADrugAReference
ANS:AA
DrugAFactsAandAComparisonsAcontainsAdrugAmonographsAthatAdescribeAallAdrugsAinA
aAtherapeuticAclass.AMonographsAareAformattedAasAtablesAtoAallowAcomparisonAofAsi
milarAproducts,AbrandAnames,Amanufacturers,AcostAindices,AandAavailableAdosageAfor
msAOnlineAversionAisAavailable.
DIF: CognitiveALevel:AKnowledge REF:Ap.A4ATableA1.2
OBJ: 3 NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
CON:ASafetyA|APatientAEducationA|AClinicalAJudgme
TOP: NursingAProcessAStep:AAssessment nt
WhichAdrugAreferenceAcontainsAmonographsAaboutAvirtuallyAeveryAsingle-
entityAdrugAavailableAinAtheAUnitedAStatesAandAdescribesAtherapeuticAusesAofAdrugs,Aincludin
gAapprovedAandAunapprovedAuses?
Martindale:ATheACompleteADrugAReference
AHFSADrugAInformation
DrugAReference
DrugAFactsAandAComparisons
ANS:AB
AHFSADrugAInformationAcontainsAmonographsAaboutAvirtuallyAeveryAsingle-
entityAdrugAavailableAinAtheAUnitedAStatesAandAdescribesAtherapeuticAusesAofAdrugs,Aincluding
AapprovedAandAunapprovedAuses.
DIF: CognitiveALevel:AKnowledge REF:Ap.A4ATableA1.2
OBJ: 3 NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
CON:ASafetyA|APatientAEducationA|AClinicalAJudgme
TOP: NursingAProcessAStep:APlanning nt
WhichAonlineAdrugAreferenceAmakesAavailableAtoAhealthcareAprovidersAandAtheApublicAaAstand
ard,Acomprehensive,Aup-to-dateAlookAupAandAdownloadableAresourceAaboutAmedicines?
AmericanADrugAIndex
AmericanAHospitalAFormulary
DailyMed
DrugAReference
ANS:AC
DailyMedAmakesAavailableAtoAhealthcareAprovidersAandAtheApublicAaAstandard,Acomprehensiv
e,Aup-to-
dateAlookAupAandAdownloadableAresourceAaboutAmedicines.ATheAAmericanADrugAIndexAisAnot
AappropriateAforApatientAuse.ATheAAmericanAHospitalAFormularyAisAnotAappropriateAforApatie
ntAuse.ATheAdrugAreferenceAisAnotAappropriateAforApatientAuse.
DIF: CognitiveALevel:AKnowledge REF: p.A3A|Ap.A4 OBJ:A3
NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
TOP:ANursingAProcessAStep:AImplementation
CON:ASafetyA|APatientAEducationA|AClinicalAJudgment
WhichAlegislationAauthorizesAtheAFDAAtoAdetermineAtheAsafetyAofAaAdrugAbeforeAitsAmarketing?
FederalAFood,ADrug,AandACosmeticAActA(1938)
DurhamAHumphreyAAmendmentA(1952)
, TestABankAForAClayton’sABasicAPharmacologyAforANursesA19thAEdition 4
ControlledASubstancesAActA(1970)
KefauverAHarrisADrugAAmendmentA(1962)
ANS:AA
TheAFederalAFood,ADrug,AandACosmeticAActAofA1938AauthorizedAtheAFDAAtoAdetermineAtheAsa
fetyAofAallAdrugsAbeforeAmarketing.ALaterAamendmentsAandAactsAhelpedAtightenAFDAAcontrolAa
ndAensureAdrugAsafety.ATheADurhamAHumphreyAAmendmentAdefinesAtheAkindsAofAdrugsAthatA
cannotAbeAusedAsafelyAwithoutAmedicalAsupervisionAandArestrictsAtheirAsaleAtoAprescriptionAbyA
aAlicensedApractitioner.ATheAControlledASubstancesAActAaddressesAonlyAcontrolledAsubstancesA
andAtheirAcategorization.ATheAKefauverAHarrisADrugAAmendmentAensuresAdrugAefficacyAandAg
reaterAdrugAsafety.ADrugAmanufacturersAareArequiredAtoAproveAtoAtheAFDAAtheAeffectivenessAo
fAtheirAproductsAbeforeAmarketingAthem.
DIF: CognitiveALevel:AKnowledge REF:AAp.A5ATableAl.3
OBJ: 5 NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
TOP:ANursingAProcessAStep:AAssessment
CON:ASafetyA|APatientAEducationA|AEvidenceA|AHealthACareALaw
WhichAclassificationAdoesAmeperidineA(Demerol)AfallAunder?
I
II
III
IV
ANS:AB
MeperidineA(Demerol)AisAaAScheduleAIIAdrug;AitAhasAaAhighApotentialAforAabuseAandAmayAleadA
toAsevereApsychologicalAandAphysicalAdependence.AScheduleAIAdrugsAhaveAhighApotentialAforA
abuseAandAnoArecognizedAmedicalAuse.AScheduleAIIIAdrugsAhaveAsomeApotentialAforAabuse.AUs
eAmayAleadAtoAlowAtoAmoderateAphysicalAdependenceAorAhighApsychologicalAdependence.ASch
eduleAIVAdrugsAhaveAlowApotentialAforAabuse.AUseAmayAleadAtoAlimitedAphysicalAorApsycholog
icalAdependence.
DIF: CognitiveALevel:AKnowledge REF: p.A10 OBJ:A2
NAT:ANCLEXAClientANeedsACategory:ASafe,AEffectiveACareAEnvironment
TOP: NursingAProcessAStep:AAssessment CON:APatientAEducationA|AAddictionA|APain
WhichAactionAwouldAtheAFDAAtakeAtoAexpediteAdrugAdevelopmentAandAapprovalAforAanAoutbr
eakAofAsmallpox?
ListAsmallpoxAasAaAhealthAorphanAdisease.
OmitAtheApreclinicalAresearchAphase.
ExtendAtheAclinicalAresearchAphase.
FastAtrackAtheAinvestigationalAdrug.
ANS:AD
OnceAtheAInvestigationalANewADrugAApplicationAhasAbeenAapproved,AtheAdrugAcanAreceiveAhi
ghestApriorityAwithinAtheAagency,AwhichAisAcalledAfastAtracking.AAAsmallpoxAoutbreakAwouldA
becomeAaApriorityAconcernAinAtheAworld.AOrphanAdiseasesAareAnotAresearchedAinAaApriorityAma
nner.APreclinicalAresearchAisAnotAomitted.AExtendingAanyAphaseAofAtheAresearchAwouldAmeanA
aAlongerAtimeAtoAdevelopAaAvaccine.ATheAFDAAmustAensureAthatAallAphasesAofAtheApreclinicalA
andAclinicalAresearchAphaseAhaveAbeenAcompletedAinAaAsafeAmanner.
DIF: CognitiveALevel:AKnowledge REF: p.A7 OBJ:A5
Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete
,Chapter 01: Drug Definitions, Standards, and Information Sources
A A A A A A A
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
A A A A A A A
MULTIPLEACHOICE
WhichAnameAidentifiesAaAdrugAlistedAbyAtheAUSAFoodAandA
DrugAAdministrationA(FDA)?
Brand
Nonproprietary
Official
Trademark
ANS:AC
TheAofficialAnameAisAtheAnameAunderAwhichAaAdrugAisAlistedA
byAtheAFDA.ATheAbrandAname,AorAtrademark,AisAtheAnameAgi
venAtoAaAdrugAbyAitsAmanufacturer.ATheAnonproprietary,AorAg
eneric,AnameAisAprovidedAbyAtheAUnitedAStatesAAdoptedANa
mesACouncil.
DIF: CognitiveALevel:AKnowledge REF:Ap.A9
OBJ:A1NAT:ANCLEXAClientANeedsACategory:ASafe,AEffectiveACare
EnvironmentATOP:AANursingAProcessAStep:AAssessment CON:
PatientAEducation
WhichAsourceAcontainsAinformationAspecificAtoAnutritionalAsupplements?
USPADictionaryAofAUSANA&AInternationalADrugANames
NaturalAMedicinesAComprehensiveADatabase
UnitedAStatesAPharmacopoeia/NationalAFormularyA(USPANF)
DrugAInteractionAFacts
ANS:AC
UnitedAStatesAPharmacopoeia/NationalAFormularyAcontainsAinformationAspecificAtoAnutrition
alAsupplements.AUSPADictionaryAofAUSANA&AInternationalADrugANamesAisAaAcompilationAofAd
rugAnames,ApronunciationAguide,AandApossibleAfutureAFDAAapprovedAdrugs;AitAdoesAnotAinclud
eAnutritionalAsupplements.ANaturalAMedicinesAComprehensiveADatabaseAcontainsAevidence-
basedAinformationAonAherbalAmedicinesAandAherbalAcombinationAproducts;AitAdoesAnotAinclude
AinformationAspecificAtoAnutritionalAsupplements.ADrugAInteractionAFactsAcontainsAcomprehen
siveAinformationAonAdrugAinteractionAfacts;AitAdoesAnotAincludeAnutritionalAsupplements.
DIF: CognitiveALevel:AKnowledge REF: p.A4 OBJ:A3
NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
TOP: NursingAProcessAStep:AAssessment CON:ANutritionA|APatientAEducation
WhichAdrugAreferenceAcontainsAdrugAmonographsAthatAdescribeAallAdrugsAinAaAtherapeuticAcla
ss?Aa.ADrugAFactsAandAComparisons
,TestABankAForAClayton’sABasicAPharmacologyAforANursesA19thAEdition 3
DrugAInteractionAFacts
HandbookAonAInjectableADrugs
Martindale—TheACompleteADrugAReference
ANS:AA
DrugAFactsAandAComparisonsAcontainsAdrugAmonographsAthatAdescribeAallAdrugsAinA
aAtherapeuticAclass.AMonographsAareAformattedAasAtablesAtoAallowAcomparisonAofAsi
milarAproducts,AbrandAnames,Amanufacturers,AcostAindices,AandAavailableAdosageAfor
msAOnlineAversionAisAavailable.
DIF: CognitiveALevel:AKnowledge REF:Ap.A4ATableA1.2
OBJ: 3 NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
CON:ASafetyA|APatientAEducationA|AClinicalAJudgme
TOP: NursingAProcessAStep:AAssessment nt
WhichAdrugAreferenceAcontainsAmonographsAaboutAvirtuallyAeveryAsingle-
entityAdrugAavailableAinAtheAUnitedAStatesAandAdescribesAtherapeuticAusesAofAdrugs,Aincludin
gAapprovedAandAunapprovedAuses?
Martindale:ATheACompleteADrugAReference
AHFSADrugAInformation
DrugAReference
DrugAFactsAandAComparisons
ANS:AB
AHFSADrugAInformationAcontainsAmonographsAaboutAvirtuallyAeveryAsingle-
entityAdrugAavailableAinAtheAUnitedAStatesAandAdescribesAtherapeuticAusesAofAdrugs,Aincluding
AapprovedAandAunapprovedAuses.
DIF: CognitiveALevel:AKnowledge REF:Ap.A4ATableA1.2
OBJ: 3 NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
CON:ASafetyA|APatientAEducationA|AClinicalAJudgme
TOP: NursingAProcessAStep:APlanning nt
WhichAonlineAdrugAreferenceAmakesAavailableAtoAhealthcareAprovidersAandAtheApublicAaAstand
ard,Acomprehensive,Aup-to-dateAlookAupAandAdownloadableAresourceAaboutAmedicines?
AmericanADrugAIndex
AmericanAHospitalAFormulary
DailyMed
DrugAReference
ANS:AC
DailyMedAmakesAavailableAtoAhealthcareAprovidersAandAtheApublicAaAstandard,Acomprehensiv
e,Aup-to-
dateAlookAupAandAdownloadableAresourceAaboutAmedicines.ATheAAmericanADrugAIndexAisAnot
AappropriateAforApatientAuse.ATheAAmericanAHospitalAFormularyAisAnotAappropriateAforApatie
ntAuse.ATheAdrugAreferenceAisAnotAappropriateAforApatientAuse.
DIF: CognitiveALevel:AKnowledge REF: p.A3A|Ap.A4 OBJ:A3
NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
TOP:ANursingAProcessAStep:AImplementation
CON:ASafetyA|APatientAEducationA|AClinicalAJudgment
WhichAlegislationAauthorizesAtheAFDAAtoAdetermineAtheAsafetyAofAaAdrugAbeforeAitsAmarketing?
FederalAFood,ADrug,AandACosmeticAActA(1938)
DurhamAHumphreyAAmendmentA(1952)
, TestABankAForAClayton’sABasicAPharmacologyAforANursesA19thAEdition 4
ControlledASubstancesAActA(1970)
KefauverAHarrisADrugAAmendmentA(1962)
ANS:AA
TheAFederalAFood,ADrug,AandACosmeticAActAofA1938AauthorizedAtheAFDAAtoAdetermineAtheAsa
fetyAofAallAdrugsAbeforeAmarketing.ALaterAamendmentsAandAactsAhelpedAtightenAFDAAcontrolAa
ndAensureAdrugAsafety.ATheADurhamAHumphreyAAmendmentAdefinesAtheAkindsAofAdrugsAthatA
cannotAbeAusedAsafelyAwithoutAmedicalAsupervisionAandArestrictsAtheirAsaleAtoAprescriptionAbyA
aAlicensedApractitioner.ATheAControlledASubstancesAActAaddressesAonlyAcontrolledAsubstancesA
andAtheirAcategorization.ATheAKefauverAHarrisADrugAAmendmentAensuresAdrugAefficacyAandAg
reaterAdrugAsafety.ADrugAmanufacturersAareArequiredAtoAproveAtoAtheAFDAAtheAeffectivenessAo
fAtheirAproductsAbeforeAmarketingAthem.
DIF: CognitiveALevel:AKnowledge REF:AAp.A5ATableAl.3
OBJ: 5 NAT:ANCLEXAClientANeedsACategory:APhysiologicalAIntegrity
TOP:ANursingAProcessAStep:AAssessment
CON:ASafetyA|APatientAEducationA|AEvidenceA|AHealthACareALaw
WhichAclassificationAdoesAmeperidineA(Demerol)AfallAunder?
I
II
III
IV
ANS:AB
MeperidineA(Demerol)AisAaAScheduleAIIAdrug;AitAhasAaAhighApotentialAforAabuseAandAmayAleadA
toAsevereApsychologicalAandAphysicalAdependence.AScheduleAIAdrugsAhaveAhighApotentialAforA
abuseAandAnoArecognizedAmedicalAuse.AScheduleAIIIAdrugsAhaveAsomeApotentialAforAabuse.AUs
eAmayAleadAtoAlowAtoAmoderateAphysicalAdependenceAorAhighApsychologicalAdependence.ASch
eduleAIVAdrugsAhaveAlowApotentialAforAabuse.AUseAmayAleadAtoAlimitedAphysicalAorApsycholog
icalAdependence.
DIF: CognitiveALevel:AKnowledge REF: p.A10 OBJ:A2
NAT:ANCLEXAClientANeedsACategory:ASafe,AEffectiveACareAEnvironment
TOP: NursingAProcessAStep:AAssessment CON:APatientAEducationA|AAddictionA|APain
WhichAactionAwouldAtheAFDAAtakeAtoAexpediteAdrugAdevelopmentAandAapprovalAforAanAoutbr
eakAofAsmallpox?
ListAsmallpoxAasAaAhealthAorphanAdisease.
OmitAtheApreclinicalAresearchAphase.
ExtendAtheAclinicalAresearchAphase.
FastAtrackAtheAinvestigationalAdrug.
ANS:AD
OnceAtheAInvestigationalANewADrugAApplicationAhasAbeenAapproved,AtheAdrugAcanAreceiveAhi
ghestApriorityAwithinAtheAagency,AwhichAisAcalledAfastAtracking.AAAsmallpoxAoutbreakAwouldA
becomeAaApriorityAconcernAinAtheAworld.AOrphanAdiseasesAareAnotAresearchedAinAaApriorityAma
nner.APreclinicalAresearchAisAnotAomitted.AExtendingAanyAphaseAofAtheAresearchAwouldAmeanA
aAlongerAtimeAtoAdevelopAaAvaccine.ATheAFDAAmustAensureAthatAallAphasesAofAtheApreclinicalA
andAclinicalAresearchAphaseAhaveAbeenAcompletedAinAaAsafeAmanner.
DIF: CognitiveALevel:AKnowledge REF: p.A7 OBJ:A5